Peter W. PENG, Author at MediaMedic

ESMO 2023 | Dr. Oliver Sartor: Lu-PSMA therapy could benefit mCRPC patients

By Peter W. PENG 2023.11.06

Prostate cancer remains a significant health concern, especially in its metastatic castration-resistant form, which poses a formidable challenge for both patients and healthcare providers. Despite ongoing advancements in treatment options, the battle against this deadly disease continues. However, recent research has illuminated a ray of hope through the use of PSMA Lutetium therapy. In this article, we delve into the insights presented by Dr. Oliver Sartor at ESMO 2023 regarding the safety, efficacy, and potential benefits of PSMA Lutetium therapy in the treatment of metastatic castration-resistant prostate cancer.

ESMO 2023 | Dr. Manuela Schmidinger: Research progress in the treatment of Renal cell carcinoma

By Peter W. PENG 2023.11.06

Renal cell carcinoma (RCC), a type of kidney cancer, has been the focus of extensive research in recent years. The recent advancements in the treatment of renal cell carcinoma have provided new hope for patients with this challenging disease. As research continues, it is crucial to individualize treatment strategies based on patient risk profiles and explore novel approaches to address the specific needs of different RCC subtypes. Further research and clinical trials will undoubtedly continue to refine and expand our understanding of these groundbreaking therapies, with the ultimate goal of enhancing the quality of life and survival rates for individuals battling RCC.

ESMO 2023 | Dr. Silke Gillessen: Biomarkers and Future Perspectives in Advanced Prostate Cancer

By Peter W. PENG 2023.11.06

Prostate cancer, a multifaceted disease, frequently progresses to an advanced stage, imposing substantial therapeutic challenges. This advanced phase comprises both metastatic and locally advanced forms, demanding innovative strategies for effective management. In recent years, the discovery and application of biomarkers have emerged as a pivotal driving force in guiding treatment decisions and elevating patient outcomes. This article will delve deeper into the fundamental challenges surrounding advanced prostate cancer, the pivotal role of biomarkers in determining treatment pathways, the utility of cutting-edge imaging techniques, and the exciting prospects of biomarker-based therapies.

IDweek2023 | Antimicrobial Utilization in Transplant Patients: A Deep Dive into Benchmarked Data

By Peter W. PENG 2023.10.27

IDweek2023 Antimicrobial Utilization in Transplant Patients: A Deep Dive into Benchmarked Data Transplant patients, encompassing those who undergo bone marrow transplants (BMT), allogeneic transplants, autologous transplants, and CAR-T procedures, represent a particularly vulnerable subgroup of the population because of their immunocompromised status. The medical management of these patients involves careful monitoring and appropriate utilization of antimicrobial agents to prevent potential infections and ensure optimal health outcomes.

IDweek2023 | A Comprehensive Examination of Racial, Ethnic, and Gender Disparities in Sepsis Treatment and Outcomes

By Peter W. PENG 2023.10.27

IDweek2023 A Comprehensive Examination of Racial, Ethnic, and Gender Disparities in Sepsis Treatment and Outcomes Sepsis, an extreme response to infection that can lead to life-threatening organ dysfunction, poses a significant global health issue. Despite advancements in healthcare, disparities in the treatment and outcomes of sepsis persist, particularly in relation to race, ethnicity, and gender. This article aims to shed light on these disparities, explore the potential underlying causes, and discuss the implications for healthcare providers and patients.

IDweek2023 | A Comprehensive Review of Outcomes in Intravenous to Oral Antimicrobial Therapy in Uncomplicated β-hemolytic Streptococcus Bloodstream Infections in Immunocompromised Individuals

By Peter W. PENG 2023.10.27

IDweek2023 A Comprehensive Review of Outcomes in Intravenous to Oral Antimicrobial Therapy in Uncomplicated β-hemolytic Streptococcus Bloodstream Infections in Immunocompromised Individuals IDweek2023 A Comprehensive Review of Outcomes in Intravenous to Oral Antimicrobial Therapy in Uncomplicated β-hemolytic Streptococcus Bloodstream Infections in Immunocompromised Individuals

IDweek2023 | A Comprehensive Analysis of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) versus Dolutegravir/Lamivudine (DTG/3TC) in HIV Treatment

By Peter W. PENG 2023.10.27

IDweek2023 A Comprehensive Analysis of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) versus Dolutegravir/Lamivudine (DTG/3TC) in HIV Treatment In the relentless battle against HIV, the advent of antiretroviral therapy (ART) has marked a significant turning point. The development and introduction of drug regimens have revolutionized HIV treatment, transforming HIV from a fatal illness into a manageable chronic condition. However, the dynamic nature of the virus and its ability to develop resistance to drugs necessitates continuous research into new treatment strategies.

IDweek2023 | The Revolutionary Shift in HIV Management: An In-Depth Analysis of Cabotegravir + Rilpivirine Long-Acting Treatment Versus Traditional Oral Antiretroviral Therapy

By Peter W. PENG 2023.10.27

IDweek2023 The Revolutionary Shift in HIV Management: An In-Depth Analysis of Cabotegravir + Rilpivirine Long-Acting Treatment Versus Traditional Oral Antiretroviral Therapy In the ever-evolving world of medicine, the ultimate goal has consistently been to enhance patient adherence and improve treatment outcomes. This is particularly apparent in the management of HIV, where antiretroviral therapy (ART) has been the cornerstone of treatment for many years. However, with the development of long-acting ART, there has been a dramatic shift in the landscape of HIV management. This comprehensive article delves into a detailed analysis of the real-world adherence and persistence of Cabotegravir + Rilpivirine Long-Acting (CAB+RPV LA) compared to oral ART among people living with HIV (PWH) in the United States. This analysis is based on the ABOVE Study, conducted by a team of researchers and healthcare professionals from ViiV Healthcare and Analysis Group, Inc.

IDweek2023 | Exploring the Consequences of Low-Level Viremia Among Women with HIV

By Peter W. PENG 2023.10.27

IDweek2023 Exploring the Consequences of Low-Level Viremia Among Women with HIV Understanding the dynamics of HIV infection is critical for managing and controlling the disease. A vital aspect of this understanding is the awareness of Low-Level Viremia (LLV), a condition experienced by about a third of people living with HIV. Despite its prevalence, there is a significant gap in clinical guidance on how to counsel and manage individuals with LLV.

IDweek2023 | Hepatitis B Reactivation in HIV Patients: A Comprehensive Study of Antiretroviral Therapy’s Role

By Peter W. PENG 2023.10.27

IDweek2023 Hepatitis B Reactivation in HIV Patients: A Comprehensive Study of Antiretroviral Therapy's Role Hepatitis B, a viral infection that primarily affects the liver, can lead to serious complications, such as cirrhosis and hepatocellular carcinoma. In individuals living with HIV, the situation is further complicated since they face the risk of Hepatitis B reactivation - a condition that can occur when switching to antiretroviral therapy (ART) lacking Hepatitis B activity. This comprehensive article explores this complex medical phenomenon, providing a detailed understanding of its causative factors, implications, and potential strategies for patient management.